CPL976H-MMAE / Celon Pharma - LARVOL DELTA

Site-specific conjugation of CPL976H-MMAE enables stable and selective dual targeting of PD-L1 and AXL (AACR 2026) - "CPL976H-MMAE effectively merges immune checkpoint blockade with targeted cytotoxicity, addressing both primary and acquired resistance to PD-1/PD-L1 therapies. High serum stability, sustained tumor accumulation, and limited systemic exposure presents CPL976H-MMAE as a formidable and robust bifunctional ADC. Presented data highlight CPL976H-MMAE translational potential for future therapies, especially for patients unresponsive to current immunotherapies.This study was supported by The National Centre for Research and Development ( POIR.01.01.01-00-0429/19)"

IO biomarker • Oncology • Solid Tumor • AXL

Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ ant-AXL antibody with a dual mechanism of action (AACR 2024) - "We presented a new, ADC based on bispecific anti-PD-L1/anti-AXL antibody conjugated with MMAE, that combines the effects of cancer growth inhibition by interaction with AXL and immunotherapy by disruption of the PD-1/PD-L1 axis, with selective delivery of MMAE to cancer cells. The simultaneous action of delivering the toxin and acting on both therapeutic targets provides a potent synergistic anti-tumor effect, that can lead to complete tumor eradication and potentially overcome the primary and secondary resistance to PD-1/PD-L1 targeted therapies."

Bispecific • IO biomarker • Oncology • AXL